1 / 19

Auritec Pharmaceutics

Auritec Pharmaceutics. Privately held Drug Delivery Platform technology Multiple applications Goal is to license 2 nd company founded by TJS. CDS. 1 st company Control Delivery Systems CDS founded 1990 First round financing $34.5 M 1999 Morgan Stanley / Cap Research / T. Rowe Price

niran
Download Presentation

Auritec Pharmaceutics

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Auritec Pharmaceutics Privately held Drug Delivery Platform technology Multiple applications Goal is to license 2nd company founded by TJS

  2. CDS 1st company Control Delivery Systems CDS founded 1990 First round financing $34.5 M 1999 Morgan Stanley / Cap Research / T. Rowe Price Public- reverse acquisition pSivida Ltd (AUS) Trades NASDAQ (PSDV)

  3. Auritec Founded 2002 Delaware C Offices Santa Monica CA, Boston MA Labs Pasadena CA Multiple academic and industry collaborators

  4. Collaborators Gates Foundation CDC CONRAD USAID IPM Charles River NC State Harvard Caltech Albert Einstein USC U Mass Emory UNC

  5. Plexis Technology Platform Injectable subcutaneous suspension Polymer encapsulation Diffusion based release Small or large molecules IVIVC feasible

  6. IV / IV release - nevirapine

  7. IV / IV release - nevirapine In vivo release

  8. IV / IV - olanzapine

  9. IV / IV - olanzapine

  10. IV / IV cyclosporine

  11. IV / IV cyclosporine

  12. Comparison to ALKS Alkermes Particle size ~100u Drug loading <20% Complex mechanism Multiphasic delivery No IVIVC Auritec Particle size ~100u Drug loading > 90% Diffusion based First and pseudo-zero order possible IVIVC feasible

  13. Existing SR injectables Risperdal Consta Leuprorelin Contraception Benzathine and procaine penicillin Zinc Insulins Corticosteroids

  14. SR injectable indications Osteoarthritis Schizophrenia Parkinson’s Diabetic retinopathy Meniere’s HIV transmission Alzheimer’s Depression Malaria TB Diabetes (GLPs) Influenza

  15. Time to Phase I/II 2010 Parkinson’s HIV Transmission Herpes Simplex Diabetic retinopathy Otoprotection Arthritis 2011 Malaria TB Incontinence Graft Rejection

  16. Business Model Bootstrap pSivida, NIH, other granting agencies Fully funded through 2011 License Sell firstborn not self Phase II clinical Non-profit for no profits

  17. Deals with Big Pharma

  18. Strategy

More Related